A harmful inherited BRCA1 or BRCA2 variant indicates increased cancer susceptibility; it is not a cancer diagnosis. Everyone has these genes. The relevant question is whether a particular change disrupts their protective function. This guide connects the genetic result to practical questions for a family, a student or a clinical team. [1]

In this guide: What does BRCA-related cancer risk mean? · Start with the right testing question · Positive, negative and uncertain are different answers · How can the result affect relatives? · What should the clinical discussion cover? · For students and researchers: read beyond the label · Choose a useful next step

What does BRCA-related cancer risk mean?

BRCA1 and BRCA2 contribute to DNA repair. Inherited pathogenic variants are associated with breast and ovarian cancer, including fallopian tube and primary peritoneal cancer, and with other cancers such as prostate and pancreatic cancer. The pattern differs between the genes. Men can inherit and transmit these variants as well as develop associated cancers. [2]

Risk should always be attached to a time period and a clearly described population. “Lifetime risk” is not the same as risk over the next five years. A study of people selected because many relatives had cancer may not describe every carrier equally well. Use our absolute and relative risk guide to check the denominator, age range and outcome behind a headline.

Start with the right testing question

  1. Write the purpose. Is testing intended to investigate family susceptibility, clarify an existing cancer diagnosis, guide cancer treatment or test for a known family variant?
  2. Bring the evidence. Obtain the actual family laboratory report when available. Record cancer types, approximate ages at diagnosis and which side of the family is affected.
  3. Confirm the sample. A tumor report and an inherited-risk report answer different questions. Ask which one you have.
  4. Read the whole result. Keep the exact variant description, classification, report date and test limitations together.
  5. Agree the follow-up. Ask who will explain the finding, arrange referrals and communicate any future reclassification.

Tumor testing can reveal a finding that warrants inherited-risk assessment, but does not replace germline testing. When feasible, assessment of a family may begin with a relative who has had cancer. [3]

Three result categories: pathogenic or likely pathogenic, uncertain significance, and negative with context.
Three result categories: pathogenic or likely pathogenic, uncertain significance, and negative with context. Educational example; see article for sources and limitations.

Positive, negative and uncertain are different answers

A pathogenic or likely pathogenic result needs clinical interpretation and a management discussion. A variant of uncertain significance (VUS) does not establish hereditary cancer susceptibility and generally should not determine management. A negative result is most informative when the laboratory specifically excluded a known causative family variant; otherwise, the family history can remain unexplained. [3]

Worked reading exercise: two relatives both say “my BRCA test was negative.” One had targeted testing for a documented family variant; the other had an older limited panel without an identified family cause. Before treating the conclusions as equivalent, ask for the reports and compare the testing question and scope. This is an illustration of report reading, not an interpretation of a real family’s results.

How can the result affect relatives?

For the usual situation of a heterozygous germline pathogenic variant, each child has a 50% chance of inheriting it. This is a transmission probability, not a 50% probability of developing cancer. Either biological parent can transmit the variant. A relative without cancer can still carry it. [4]

A useful family summary has three separate columns: relationship, documented cancer history, and documented genetic test result. Mark unknown information as unknown. Do not label an untested person negative, and do not infer a carrier result from a cancer diagnosis alone. Read cascade testing for a structured approach to a known family finding.

What should the clinical discussion cover?

Possible approaches include enhanced surveillance and risk-reducing interventions. The balance depends on the gene, age, organs present, personal history, reproductive plans and preferences. Ovarian cancer screening has important limitations; a reassuring screening test should not be presented as equivalent to risk reduction. Use current specialist guidance to decide a personal plan. [4]

  • Which cancer risks apply to this gene and to my circumstances?
  • Which screening measures are recommended now, and who will arrange them?
  • What benefit, harm and uncertainty accompany each preventive option?
  • Which relatives could benefit from counseling and targeted testing?
  • What decisions are urgent, and which allow time for further discussion?

For students and researchers: read beyond the label

A paper about BRCA-positive tumors may combine inherited variants, tumor-only findings or different variant classes. Extract the study’s definition before comparing outcomes. Keep susceptibility, tumor biology and treatment response in separate columns. The tumor versus germline guide explains the distinction.

BRCA1 and BRCA2 variants also have gene-specific expert classification resources through ClinGen ENIGMA. Record the version and evidence behind an interpretation rather than treating a search-engine summary as the final assessment. [5]

Choose a useful next step

Continue with the BRCA1 gene guide and BRCA2 gene guide for molecular detail. Use the variant research assistant to organize an exact, non-identifying query, the care finder for professional directories, and the research tools to locate original studies. The disease finder helps explore related conditions.

Educational information, not an individual diagnosis or treatment plan. The current specialist-review status appears above. Illustrations are original educational examples, not patient records.